CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Little Green Pharma Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Little Green Pharma Ltd
PO Box 690
Phone: +61 862800050p:+61 862800050 PERTH, WAS  6872  Australia Ticker: LGPLGP
Business Summary
Little Green Pharma Ltd is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution. The Company has two global production sites for the manufacture of its own-branded and white-label ranges of Good Manufacturing Practice (GMP)-grade medicinal cannabis products, being a 21,500 square meters cultivation and 4,000 square meters GMP manufacturing facility capable of producing over 30 tons of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing three tons of medicinal cannabis biomass per annum. The Company focuses on patient access in the global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop new delivery systems.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20233/31/2023Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Michael D.Lynch-Bell 70
Chief Executive Officer PaulLong 8/29/2023
Managing Director, Executive Director FletaSolomon
4 additional Officers and Directors records available in full report.

Business Names
Business Name
LGP
Spectrum Therapeutics

General Information
Outstanding Shares: 300,093,234 (As of 9/30/2023)
Shareholders: 11,782
Stock Exchange: ASX
Fax Number: +61 863234697


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024